Table 1. Baseline clinical characteristics of the previous validation and current PAM cohorts.
| Factor | Previous Cohort† | Current Cohort† |
|---|---|---|
| Patient age, years, median (range) | 41.8 (15.0-72.5) | 50.7 (15.1-78.9) |
|
| ||
| Disease risk,* N (%) | ||
| Low | 382 (29) | 237 (15) |
| Intermediate | 358 (27) | 885 (57) |
| High | 574 (44) | 427 (28) |
|
| ||
| Donor type, N (%) | ||
| Related/Matched | 670 (51) | 584 (38) |
| Related/Mismatched | 125 (10) | 79 (5) |
| Unrelated | 519 (39) | 886 (57) |
|
| ||
| Conditioning, N (%) | ||
| Reduced intensity | 72 (5) | 609 (39) |
| Myeloablative, no TBI | 469 (36) | 547 (35) |
| Myeloablative, TBI ≤ 12 Gy | 326 (25) | 253 (16) |
| Myeloablative, TBI > 12 Gy | 497 (34) | 140 (9) |
|
| ||
| Creatinine, mg/dL, median (range) | 0.8 (0.3-5.7) | 0.9 (0.3-9.7) |
|
| ||
| ALT, U/mL, median (range) | 27 (0-908) | 23 (4-349) |
|
| ||
| FEV1, percent of predicted, median (range) | 93.1 (26.4-100) | 92.2 (32.0-100) |
|
| ||
| DLCO, percent of predicted, median (range) | 99.2 (9.7-100) | 80.0 (31.2-100) |
Abbreviations: TBI, total-body irradiation; HCT, hematopoietic cell transplant; ALT, alanine aminotransferase; DLCO, carbon monoxide diffusing capacity
*
Categorized according to reference 1.
†
Date range October 1, 1990 through December 31, 2002 for the previous cohort compared with January 1, 2003 through December 31, 2009 for the current cohort.